News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
674,501 Results
Type
Article (38551)
Company Profile (191)
Press Release (635759)
Section
Business (202843)
Career Advice (1957)
Deals (35333)
Drug Delivery (74)
Drug Development (80450)
Employer Resources (167)
FDA (15929)
Job Trends (14751)
News (342690)
Policy (32379)
Tag
Academia (2524)
Africa (708)
Allergies (37)
Alliances (48858)
Alzheimer's disease (1093)
Antibody-drug conjugate (ADC) (43)
Approvals (15872)
Arizona (159)
Artificial intelligence (48)
Asia (36566)
Australia (5944)
Bankruptcy (350)
Best Places to Work (11171)
Biosimilars (55)
C2C Services and Suppliers (78801)
California (820)
Canada (641)
Cancer (176)
Career advice (1635)
CAR-T (32)
Cell therapy (65)
China (48)
Clinical research (62578)
Collaboration (56)
Colorado (33)
Compensation (30)
COVID-19 (2452)
Cystic fibrosis (69)
Diabetes (32)
Diagnostics (5888)
Diversity, equity & inclusion (44)
Drug pricing (47)
Earnings (82757)
Employer resources (141)
Europe (78085)
Events (106897)
FDA (15973)
Florida (106)
Funding (37)
Gene therapy (52)
GLP-1 (465)
Government (4272)
Healthcare (18525)
Hotbed/Location (481032)
Idaho (55)
Illinois (194)
Indiana (105)
Infectious disease (2465)
Inflammatory bowel disease (83)
Interviews (305)
IPO (16114)
Job creations (3616)
Job search strategy (1410)
Kansas (90)
Layoffs (372)
Legal (7814)
Liver cancer (51)
Lung cancer (37)
Maine (47)
Management (53)
Manufacturing (45)
Maryland (251)
Massachusetts (450)
Medical device (12944)
Medtech (12947)
Mergers & acquisitions (18920)
Metabolic disorders (154)
Neuroscience (1170)
New Jersey (62)
New York (83)
NextGen Class of 2024 (6445)
Non-profit (4441)
North Carolina (158)
Obesity (101)
Opinion (160)
Parkinson's disease (29)
Patents (33)
Peanut (33)
Pennsylvania (55)
People (55519)
Phase I (19399)
Phase II (27567)
Phase III (20608)
Policy (33)
Postmarket research (2544)
Preclinical (8270)
Rare diseases (89)
Real estate (5877)
Recruiting (63)
Regulatory (21012)
Reports (32)
Research institute (2297)
Resumes & cover letters (343)
South America (1085)
Startups (3547)
Texas (87)
United States (3002)
Vaccines (408)
Washington State (113)
Weight loss (96)
Date
Today (45)
Last 7 days (496)
Last 30 days (1907)
Last 365 days (38257)
2024 (21596)
2023 (40074)
2022 (51174)
2021 (55713)
2020 (54087)
2019 (46542)
2018 (35020)
2017 (32111)
2016 (31480)
2015 (37554)
2014 (31318)
2013 (26346)
2012 (28570)
2011 (29263)
2010 (27329)
674,501 Results for "theratechnologies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
Theratechnologies Inc. Today announced the Company will report financial results and provide a business update for its second quarter ended May 31, 2024, on Wednesday, July 10 at 8:30 a.m. ET.
June 26, 2024
·
1 min read
Theratechnologies Reports on its Annual Meeting of Shareholders - May 09, 2024
Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held in a virtual-only setting.
May 9, 2024
·
1 min read
Theratechnologies Announces Update on its Preclinical Oncology Research Program
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will phase down its preclinical oncology research activities.
March 22, 2024
·
6 min read
Business
Theratechnologies Appoints Elina Tea to its Board of Directors
Theratechnologies Inc. announced the appointment of Elina Tea, Chief Financial Officer at GLS North America, to its Board of Directors and as a member of the Company’s Audit Committee.
April 5, 2024
·
6 min read
Drug Development
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Theratechnologies Inc. today announced moving to the next dose level in Part 3 of its Phase 1 clinical trial of sudocetaxel zendusortide in patients with advanced ovarian cancer.
March 21, 2024
·
7 min read
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Theratechnologies Inc. today announced that the Company’s President and CEO, Paul Lévesque will be presenting at the 2024 Bloom Burton & Co. Healthcare Investor Conference, which is taking place April 16-17 in Toronto, Canada.
April 11, 2024
·
1 min read
Drug Development
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that highlight the versatility and flexibility of the Company’s SORT1+ Technology™ platform.
April 8, 2024
·
8 min read
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
Theratechnologies Inc. announced Phase 1 data demonstrating signs of long-term efficacy and a manageable safety profile of its lead investigational peptide drug conjugate candidate, sudocetaxel zendusortide, in patients with solid tumors.
May 23, 2024
·
9 min read
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced two posters will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024.
March 28, 2024
·
6 min read
Business
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
Theratechnologies Inc. today reported business highlights and financial results for the first quarter of fiscal year 2024 ended February 29, 2024 (Q1 2024).
April 10, 2024
·
22 min read
1 of 67,451
Next